Many studies demonstrated that GPC3 peptide vaccine triggers immune response in the patients with advanced hepatocellular carcinoma and the level of immune response was associated with overall survival [ 50- 51]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.